Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →
| Demonstração de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receita total | $4.6B | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $2.2B | $1.9B | $1.6B | $1.5B | $1.3B | $1.2B | $872M | $586M | $272M | $174M | $128M | $68M | $65M | $45M |
| Lucro bruto | $3.9B | $3.8B | $3.6B | $3.4B | $3.1B | $2.7B | $2.2B | $2.0B | $1.8B | $1.5B | $1.4B | $1.2B | $1.1B | $770M | $508M | $258M | $160M | $119M | $54M | $56M | $38M |
| Margem Bruta % | 84.7% | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% | 92.3% | 90.0% | 88.3% | 86.6% | 94.9% | 92.2% | 92.5% | 79.4% | 86.4% | 84.5% |
| Resultado Operacional (EBIT) | — | $224M | $717M | $579M | ($66M) | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | $340M | $198M | $128M | $58M | $16M | ($170M) | ($139M) | ($78M) |
| % de margem operacional | — | 5.3% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% | 38.4% | 16.7% | 39.0% | 33.8% | 46.9% | 33.2% | 12.4% | -252.3% | -212.5% | -174.0% |
| Resultado líquido | $940M | ($356M) | $560M | $415M | ($224M) | ($329M) | $239M | $523M | $447M | $488M | $397M | $330M | $58M | $216M | $289M | $125M | $33M | ($7M) | ($184M) | ($139M) | ($59M) |
| Margem Líquida % | 20.4% | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% | 24.9% | 5.0% | 24.8% | 49.2% | 45.9% | 18.9% | -5.3% | -273.0% | -212.6% | -132.4% |
| EBITDA | — | $108M | $1.5B | $1.4B | $1.5B | $1.0B | $1.0B | $1.0B | $933M | $779M | $754M | $666M | $584M | $454M | $310M | $134M | $54M | $25M | ($126M) | ($128M) | ($68M) |
| Lucro por ação (EPS) | $14.63 | $-5.84 | $8.49 | $5.76 | $-3.58 | $-5.51 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $0.83 | $-0.23 | $-7.19 | $-10.04 | $-4.41 |
| Ações em circulação (M) | — | 61M | 66M | 72M | 63M | 60M | 57M | 58M | 61M | 61M | 62M | 63M | 63M | 62M | 60M | 47M | 39M | 30M | 26M | 14M | 13M |
Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.
Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de JAZZ. /companies/us/JAZZ
As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.
About TickerBase · Data methodology & sources · Privacy · Terms